Evidence map›Paper›PMID 40508224›Full record

ReviewInternational journal of molecular sciences2025

Molecular Basis of Anxiety: A Comprehensive Review of 2014-2024 Clinical and Preclinical Studies.

Ermis Merkouris, Alexandra Brasinika, Meropi Patsiavoura, Chrysanthi Siniosoglou, Dimitrios Tsiptsios, Andreas S Triantafyllis, Christoph Mueller, Ioulia Mpikou, Myrto T Samara, Nikolaos Christodoulou and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. ACS omega · 2026
    Article
  3. Article
  4. Article
  5. Joint nausea and fatigue profiles during chemotherapy identify patients with a higher symptom burden.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ermis MerkourisNeurology Department, Democritus University of Thrace, 68100 Alexandroupoli, Greece.ORCID 0009-0000-6664-4405
Alexandra Brasinika3rd Neurology Department, Aristotle University, 54124 Thessaloniki, Greece.
Meropi Patsiavoura3rd Neurology Department, Aristotle University, 54124 Thessaloniki, Greece.
Chrysanthi Siniosoglou3rd Neurology Department, Aristotle University, 54124 Thessaloniki, Greece.
Dimitrios TsiptsiosNeurology Department, Democritus University of Thrace, 68100 Alexandroupoli, Greece.ORCID 0000-0002-1601-8788
Andreas S TriantafyllisDepartment of Cardiology, Asklepeion General Hospital, 16673 Athens, Greece.ORCID 0000-0002-8037-463X
Christoph MuellerInstitute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London SE5 8AB, UK.ORCID 0000-0001-9816-1686
Ioulia MpikouDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Dragana, 68100 Alexandroupolis, Greece.
Myrto T SamaraDepartment of Psychiatry, Faculty of Medicine, University of Thessaly, 41110 Larisa, Greece.
Nikolaos ChristodoulouDepartment of Psychiatry, Faculty of Medicine, University of Thessaly, 41110 Larisa, Greece.
Konstantinos TsamakisInstitute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London SE5 8AB, UK.ORCID 0000-0002-0063-8413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anxiety disorders are among the most common psychiatric conditions that significantly impair one's quality of life and place a significant burden on healthcare systems. Conventional treatments have certain restraints, such as potential side effects and limited efficacy. Τhe underlying pathophysiological mechanisms of anxiety are not fully understood. A comprehensive literature search was performed in MEDLINE and Scopus databases for original English-language articles published between January 2014 and December 2024. Study selection, data extraction, and screening were independently carried out by multiple investigators using predefined criteria. Our review aimed to help better comprehend the molecular basis of anxiety, focusing on the hypothalamic-pituitary-adrenal (HPA) axis, serotonergic signaling, and gamma-aminobutyric acid (GABA) neurotransmission. In addition, we addressed the role of epigenetics and pharmacogenomics in personalized treatment. Although novel anxiety treatments are promising, they are predominantly preclinical and highly heterogeneous, which poses a challenge to achieving reliable therapeutic efficacy. Our findings could potentially contribute to the development of new therapeutic interventions. Further research is warranted, especially in human subjects, with an aim to combine genetic and epigenetic profiles to refine treatment approaches and develop innovative therapeutics.

Indexed as

AnxietyAnxiety DisordersAnimalsEpigenesis, Geneticgamma-Aminobutyric AcidHumansHypothalamo-Hypophyseal SystemPituitary-Adrenal Systemgamma-Aminobutyric Acidanxietygeneticmechanismsmolecularneurobiologicalstresstreatment

Identifiers

PMID40508224
PMCPMC12155146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.